1 2 3 A 4-year review of amniocentesis at a tertiary hospital in Ethiopia: an experience 4 from a LMIC 5 6 7 Haile G. Mekuria^{1*}, Hilkiah K. Suga^{2†}, Gadise Bekele³ 8 9 ¹Department of Obstetrics and Gynecology, Myungsung Medical College/MCM 10 Comprehensive Specialized Hospital, Addis Ababa, Ethiopia 11 ²Department of Research, Blue Health Medical Consultancy, Addis Ababa, Ethiopia 12 ³Department of Biostatistics, Addis Continental Institute of Public Health, Addis Ababa, 13 14 Ethiopia 15 *First author 16 [†]Corresponding author: hilkms@gmail.com 17

Abstract

- 19 Background: Amniocentesis is a technique for withdrawing amniotic fluid from the
- uterine cavity using a needle via a trans-abdominal approach. It has multiple diagnostic
- 21 and therapeutic uses such as prenatal genetic studies and amnioreduction for
- 22 polyhydramnios. The commonest indications are advanced maternal age and increased
- risk on maternal serum screening. The objective of this study is to review the common
- 24 indications, outcomes and complications of amniocentesis at a tertiary hospital in
- 25 Ethiopia.
- Methods: A retrospective cross-sectional study was conducted at a tertiary hospital in
- 27 Ethiopia. Data was collected from the Fetomaternal division's log records and follow-up
- 28 charts during the time period of 2019 to 2022. All records of patients who had
- 29 amniocentesis done were included in the study. Socio-demographic information and
- 30 obstetric history and variables related to the procedures were retrieved. Descriptive
- 31 statistics was done using the software IBM Statistical Package for Social Sciences
- 32 (SPSS) version 25.
- Results: A total of 35 patients' records were reviewed. The mean maternal age was 32
- years (range, 19 43 years). The mean gestational age was 20.9 weeks (SD \pm 2.2).
- 35 The commonest indications for amniocentesis were previous history of Down syndrome
- 36 (11%), advanced maternal age (9%) and QUAD 1:200 for Down syndrome (6%).
- 37 Karyotype test was done in 29 of the 35 amniocentesis cases which was normal in 72%
- of the cases, 17% had Trisomy-21 and 11% had Trisomy-18. Fifty-two percent of the
- pregnancy had a live full term delivery and 25% of the cases terminated the pregnancy.
- 40 Conclusion: The most common indications for amniocentesis in Ethiopia were abnormal
- 41 ultrasound finding, advanced maternal age and abnormal QUAD test results. Around a
- 42 quarter of the genetic tests which were done after the procedure had chromosomal
- 43 abnormalities, from which, the majority were terminated. There was no complication
- related to the procedure.
- Keywords: amniocentesis, advanced maternal age, prenatal genetic study,
- 46 chromosomal abnormality, fetomaternal complication

Introduction

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

Amniocentesis is a technique for withdrawing amniotic fluid from the uterine cavity using a needle via a trans-abdominal approach. Amniocentesis has been widely used since it was first performed in 1956. Originally reported as a method of determining fetal sex in utero, Fuchs and Riis then hypothesized that it could be possible to diagnose chromosomal abnormalities in utero via this technique. By 1963, it had been confirmed that the karyotype of fetal and amniotic cells are identical (1 - 3). The most common diagnostic indications for obtaining amniotic fluid are prenatal genetic studies and assessment of fetal lung maturity. Other indications include, but are not limited to, evaluation of the fetus for infection, degree of hemolytic anemia, blood or platelet type, hemoglobinopathy, and neural tube defects. Risks include spontaneous abortion, infection, needle injuries, and preterm labor (4, 5). Amniocentesis is also performed as a therapeutic procedure to remove excess amniotic fluid, such as in symptomatic polyhydramnios or twin-twin transfusion syndrome, or to reduce volume and pressure of amniotic fluid in cases of prolapsed fetal membranes in the second trimester to facilitate placement of an emergency cerclage.(6, 7) Since the late 1960s, amniocentesis has become a widely accepted method of obtaining fetal genetic information (8). Amniocentesis for prenatal genetic studies is technically possible at any gestational age after approximately 11 weeks of gestation, but is optimally performed after 15 to 17 weeks of gestation. Procedures performed before 15 weeks (ie, early amniocentesis) are associated with higher fetal loss and complication rates, including culture failure, and should be avoided. Later procedures

can be problematic if termination of pregnancy is planned based upon abnormal results. Although some pain is associated with amniocentesis, it is generally well tolerated without the need for anesthesia (8, 9). Maternal age over 35 is the most common indication for amniocentesis (10). It is conventionally performed between 16 – 24 weeks. The chances of late-onset abnormalities after 1st and 2nd-trimester ultrasound examinations are estimated at 5.5%-17% (11). Counseling about the risk and benefit of the procedure is very important as some women may decline the procedure if they don't want to terminate the pregnancy whatever the result is. Others, even if they don't want to terminate the pregnancy, they accept the procedure to prepare themselves for the care of the baby after delivery (12). Prenatal chromosomal microarray analysis is recommended for a patient with a fetus with one or more major structural abnormalities identified on ultrasonographic examination and who is undergoing invasive prenatal diagnosis (13). Even though the procedure is more than 6 decades old, as far as the authors search goes, this report is the first of its kind from an experience located in the Eastern Africa. This study aims to review the common indications and outcomes of prenatal diagnostic amniocentesis and its complications at a tertiary center in Ethiopia. Methods

87

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

88

89

A retrospective cross-sectional study was conducted at the Fetomaternal division,

Department of Obstetrics and Gynecology, MCM Comprehensive Specialized Hospital,

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

Addis Ababa, Ethiopia. The department is one of the few in the country that gives prenatal amniocentesis service. Data was collected from the division's log records and follow-up charts which was abstracted from 2019 to 2022. Study period was from June 1st to 30th, 2023. Records of all patients who had prenatal amniocentesis done during the timeframe were included in the study. The following variables were collected: indication, maternal age, gestational age, needle size, BMI, pregnancy outcome, result of the genetic test, presence of vaginal bleeding post-procedure, presence of amnionitis. The procedures were carried out by the same fetomaternal specialist using the same ultrasound guided techniques. IBM Statistical Package for Social Sciences (SPSS) version 25 was used to compute descriptive statistics. Ethical approval was obtained prior to the data collection and the investigators did not collect personal identification information of the patients. Results A total of 35 women had amniocentesis between 2019 and 2022 with the mean maternal age was 32 years (range, 19 – 43 years). The mean gestational age was 20.9 weeks (SD \pm 2.2, range 17 – 25) and mean maternal BMI was 21 kg/m2 (SD \pm 2.4). In 23 patients, 20 Gauge needle was used and 22 Gauge was used in the others. The

and parallel in 5 of the procedures (15%).

The commonest indications were previous history of down syndrome (11%), advanced maternal age (9%), cleft lip (6%), history of Recurrent pregnancy loss or RPL (6%),

needle insertion to the probe angle was perpendicular in 30 of the procedures (85%)

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

hydrocephalus (6%), non-immune hydrops (6%), omphalocele (6%), QUAD 1:200 for down syndrome (6%). Karyotype test was done in 29 of the 35 amniocentesis cases. Karyotype results were normal in 72% of cases (21/29), Trisomy-21 in 17% (5/29) and Trisomy-18 in 11% (3/29). Almost half (52%) of the cases had a live birth, 46% (16/35) had a term delivery and 6% (2/35) had a preterm delivery. Stillbirth or miscarriage occurred in 17% (6/35), 25% (9/35) of the cases terminated the pregnancy and the outcome was not known in 6% (2/35) of the cases. Pathological ultrasonography has the highest positive detection rate (30%) Discussion Amniocentesis is generally done after the 15th gestational week with a miscarriage risk of less than 1% (14, 15). The risk of spontaneous fetal losses following amniocentesis preformed before this gestational age increases (16). Likewise, the patients in our study were between the gestational age of 17 and 25 weeks, which were under the accepted gestational age range. Currently twenty and twenty-two gauge needles are commonly used and in this study. two-third of the procedure was done using a 20G needle. The larger needle size i.e. 20G is associated with significantly shorter duration of amniocentesis. However, there is no significant difference in the intrauterine bleeding at the insertion site and fetal loss (17, 18). Likewise, none of the patients in this study had documented intrauterine bleeding in both groups (20G vs 22G).

A study done in South East China that did a retrospective analysis on more than 4700 patients who had an amniocentesis showed the commonest indications for amniocentesis were increased risk on maternal serum screenings and advanced maternal age. They are indications for 86% of the procedures (5). Another 5 year reviews from Malaysia and China hospitals showed similar findings i.e. both indications accounted for more than half of the total procedures (19, 20). Other common indications include poor obstetric history, pathological ultrasonography findings and positive results from non-invasive prenatal testing. However, in our study, the majority of indication for amniocentesis was done due to the pathological ultrasonography findings (57% vs 12% or 4%) followed by previous Down syndrome baby and increased risk on maternal serum screenings, each accounted for 11% of the procedures. Advanced maternal age was an indication in only 9% of cases.

Positive detection rate of pathological ultrasonography for chromosomal abnormalities is less than 15% (19, 20). Noninvasive prenatal DNA testing has the highest positive detection rate with greater than 40% (42% and 53%). In our study, pathological ultrasonography has the highest positive detection rate (30%).

Conclusion

A review of the first 5 years of amniocentesis at our center showed that the most common indication to the procedure was abnormal ultrasound finding. Advanced maternal age and abnormal QUAD test results were also among the common indications. Around a quarter of the genetic tests which were done after the procedure had chromosomal abnormalities, from which, the majority were terminated. There was

- no complication related to the procedure. Further study is required to understand more
- 155 fetomatenal complications of amniocentesis in Ethiopia.

Reference

- (1) FUCHS F, RIIS P. Antenatal sex determination. Nature. 1956 Feb 18;177
- 158 (4503):330. doi: 10.1038/177330a0. PMID: 13297032.
- (2) Connolly KA, Eddleman KA. Amniocentesis: A contemporary review. World J Obstet
- 160 Gynecol 2016; 5(1): 58-65 [DOI: 10.5317/wjog.v5.i1.58]
- 161 (3) Steele MW, Breg WR Jr. Chromosome analysis of human amniotic-fluid cells.
- Lancet. 1966 Feb 19;1(7434):383-5. doi: 10.1016/s0140-6736(66)91387-0. PMID:
- 163 4159775.
- (4) Bornstein E, Lenchner E, Donnenfeld A, Barnhard Y, Seubert D, Divon MY.
- Advanced maternal age as a sole indication for genetic amniocentesis; risk-benefit
- analysis based on a large database reflecting the current common practice. J Perinat
- Med. 2009;37(2):99-102. doi: 10.1515/JPM.2009.032. PMID: 18999912.
- 168 (5) Tao H, Xiao J, Yang C, Wang J, Tang Y, Guo C, Wang J. Retrospective analysis of
- 4761 cases who underwent amniocentesis in southeast China. J Obstet Gynaecol. 2018
- Jan;38(1):38-41. doi: 10.1080/01443615.2017.1326887. Epub 2017 Aug 1. PMID:
- 171 28764586.
- (6) Erfani H, Diaz-Rodriguez GE, Aalipour S, Nassr A, Rezaei A, Gandhi M, Mendez-
- Figueroa H, Aagaard KM, Shamshirsaz AA. Amnioreduction in cases of
- polyhydramnios: Indications and outcomes in singleton pregnancies without fetal
- interventions. Eur J Obstet Gynecol Reprod Biol. 2019 Oct;241:126-128. doi:
- 176 10.1016/j.ejogrb.2019.05.019. Epub 2019 May 19. PMID: 31160132.
- (7) Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org;
- Dashe JS, Pressman EK, Hibbard JU. SMFM Consult Series #46: Evaluation and
- management of polyhydramnios. Am J Obstet Gynecol. 2018 Oct;219(4):B2-B8. doi:
- 180 10.1016/j.ajog.2018.07.016. Epub 2018 Jul 23. PMID: 30048635.
- 181 (8) Daum H, Ben David A, Nadjari M, Zenvirt S, Helman S, Yanai N, Meiner V, Yagel S,
- Frumkin A, Shkedi Rafid S; collaborating authors. Role of late amniocentesis in the era
- of modern genomic technologies. Ultrasound Obstet Gynecol. 2019 May:53(5):676-685.
- doi: 10.1002/uog.20113. Epub 2019 Apr 12. PMID: 30155922.
- (9) Practice Bulletin No. 162: Prenatal Diagnostic Testing for Genetic Disorders. Obstet
- 186 Gynecol. 2016 May;127(5):e108-e122. doi: 10.1097/AOG.00000000001405. PMID:
- 187 26938573.

- (10) Papp C, Papp Z. Chorionic villus sampling and amniocentesis: what are the risks in
- current practice? Curr Opin Obstet Gynecol. 2003 Apr;15(2):159-65. doi:
- 190 10.1097/00001703-200304000-00011. PMID: 12634608.
- (11) Quinlan MP. Amniocentesis: indications and risks. Virtual Mentor. 2008 May
- 192 1;10(5):304-6. doi: 10.1001/virtualmentor.2008.10.5.cprl1-0805. PMID: 23211983.
- 193 (12) Bardin R, Hadar E, Haizler-Cohen L, Gabbay-Benziv R, Meizner I, Kahana S,
- 194 Yeshaya J, Yacobson S, Cohen-Vig L, Agmon-Fishman I, Basel-Vanagaite L, Maya I.
- 195 Cytogenetic analysis in fetuses with late onset abnormal sonographic findings. J Perinat
- 196 Med. 2018 Nov 27;46(9):975-982. doi: 10.1515/jpm-2017-0071. PMID: 28915119.
- 197 (13) Committee on Genetics and the Society for Maternal-Fetal Medicine. Committee
- Opinion No.682: Microarrays and Next-Generation Sequencing Technology: The Use of
- Advanced Genetic Diagnostic Tools in Obstetrics and Gynecology. Obstet Gynecol.
- 200 2016 Dec;128(6):e262-e268. doi: 10.1097/AOG.00000000001817. PMID: 27875474.
- 201 (14) Odibo AO, Gray DL, Dicke JM, Stamilio DM, Macones GA, Crane JP. Revisiting the
- fetal loss rate after second-trimester genetic amniocentesis: a single center's 16-year
- 203 experience. Obstet Gynecol. 2008 Mar;111(3):589-95. doi:
- 204 10.1097/AOG.0b013e318162eb53. PMID: 18310360.
- 205 (15) Salomon LJ, Sotiriadis A, Wulff CB, Odibo A, Akolekar R. Risk of miscarriage
- following amniocentesis or chorionic villus sampling: systematic review of literature and
- updated meta-analysis. Ultrasound Obstet Gynecol. 2019 Oct;54(4):442-451. doi:
- 208 10.1002/uog.20353. Epub 2019 Sep 6. PMID: 31124209.
- 209 (16) Saltvedt S, Almström H. Fetal loss rate after second trimester amniocentesis at
- different gestational age. Acta Obstet Gynecol Scand. 1999 Jan;78(1):10-4. PMID:
- 211 9926885.
- 212 (17) Athanasiadis A, Petrakis P, Mikos T. Comparison of perinatal outcome after 2nd
- trimester amniocentesis using 22G and 20G needle. Hippokratia. 2017 Jan-
- 214 Mar;21(1):60. PMID: 29904263; PMCID: PMC5997025.
- 215 (18) Athanasiadis AP, Pantazis K, Goulis DG, Chatzigeorgiou K, Vaitsi V,
- 216 Assimakopoulos E, Tzevelekis F, Tsalikis T, Bontis JN. Comparison between 20G and
- 22G needle for second trimester amniocentesis in terms of technical aspects and short-
- 218 term complications. Prenat Diagn 2009; 29: 761-765 [PMID: 19412914 DOI:
- 219 10.1002/pd.2283]
- (19) Jummaat F, Ahmad S, Mohamed Ismail NA. 5-Year review on amniocentesis and
- its maternal fetal complications. Horm Mol Biol Clin Investig. 2019 Sep

20;40(2):/j/hmbci.2019.40.issue-2/hmbci-2019-0006/hmbci-2019-0006.xml. doi:
 10.1515/hmbci-2019-0006. PMID: 31539354.
 (20) Liu Y, Sun XC, Lv GJ, Liu JH, Sun C, Mu K. Amniotic fluid karyotype analysis and prenatal diagnosis strategy of 3117 pregnant women with amniocentesis indication. J
 Comp Eff Res. 2023 May 31;12(6):e220168. doi: 10.57264/cer-2022-0168. Epub ahead of print. PMID: 37256256; PMCID: PMC10402904.

Table 1: A five year summary of genetic test results and indications for amniocentesis at MCM Comprehensive Specialized Hospital, 2019 – 2022

230

Genetic tes	t result		Number of cases	Percenta ge (denomina tor being the subtotal, %)	Percentag e (denominat or being the grand total, %)
Normal	Indication for	Advanced maternal	2	9.52	5.71
Karyotype	amniocentesis	age			
		Pathological	12	57.14	34.28
		ultrasonography			
		findings			
		History of recurrent	1	4.76	2.86
		pregnancy loss			
		Previous history of	1	4.76	2.86
		MR baby			
		Previous hx of Down	4	19.05	11.43
		Syndrome			
		QUAD 1:200 for Down	1	4.76	2.86
		Syndrome			
	Total		21	100	60
Trisomy	Indication for	Pathological	5	100	14.29
21	amniocentesis	ultrasonography			
		findings			
	Total		5	100	14.29
Trisomy	Indication for	Pathological	1	33.33	2.86
18	amniocentesis	ultrasonography			
		findings			
		History of still birth	1	33.33	2.86
		QUAD 1:10 for	1	33.33	2.86
		trisomy 18			
	Total		3	100	8.57

Not	Indication for	Advanced maternal	1	16.67	2.86
determine	amniocentesis	age			
d		Pathological	2	33.33	5.71
		ultrasonography			
		findings			
		History of RPL	1	16.67	2.86
		QUAD 1:150 for Down	1	16.67	2.86
		Syndrome			
		QUAD 1:200 for Down	1	16.67	2.86
		Syndrome			
	Total		6	100	17.14
Grand total			35		100

232233

Table 2: Pregnancy outcomes and genetic test results of women who had amniocentesis at MCM Comprehensive Specialized Hospital, 2019 – 2022

235

236

	Genetic test result			Total	
		Normal	Trisomy	Not	
			18 or 21	determined	
Pregnancy	Term delivery	12	0	4	16
outcome	Preterm delivery	2	0	0	2
	Terminated	1	7	1	9
	Still birth	5	1	0	6
	Unknown	1	0	1	2
Total		21	8	6	35